INTRODUCTION
As stated in the European guidelines for quality assurance in mammography screening, the objective of screening for breast cancer is to reduce morbidity and mortality from the disease without adversely affecting the health status of those who participate in screening (1). The effectiveness of ap rogramme therefore relies on the quality, organisation, and population acceptability.
When organising as creening programme, baseline epidemiologicald atai sap rerequisiteu pon whicht he outcomem easureso fm ammography screening must be compared, since am ore favourable stage distribution in screen-detected cancers compared to clinically diagnosed cancers forms the basis of the mortality reduction (2). It has repeatedly been shown that tumour stage correlates with survival in breast cancer (3, 4 ).
An early predictor of the effect of screening on breast cancer mortality is therefore an indubitable increase in early stage breast cancer incidence with the onset of screening, and asubsequent decrease in more advanced stage breast cancer incidence (5).
The obtained change in stage distribution brought about by screening should also result in ahigher de-gree of breast conserving therapy and ad ecrease in need of adjuvant treatment (6). Among the adverse effects of screening is the risk of afalse positive mammography leading to ac ertain number of healthy women recalled for further assessment, and, further, the risk of overdiagnosis with mammographic detection of small, indolent malignancies, that might not have surfaced clinically in the absence of screening.
In order to monitor the effects of as creening programme theE uropeang uidelinesh aves et up performance indicators stating acceptable levels for the quality of the screening process, and early surrogate indicators by which the impact of ab reast cancer screening programme can be assessed (1). These indicators are used as surrogate measures of the likelihood of achieving as ubsequent mortality reduction (7).
This review focuses on the clinical impact of introduction of mammography screening, exemplified by comparison of tumour stage and treatment of breast cancer detected by mammography screening with clinically detected breast cancers.
MATERIALS AND METHODS
Review of literature on the introduction of mammography screening, performed as asearch in the Pubmed database.
The results are compared to recommended levels of performance and impact indicators for assessment in mammography screening as they are stated in European guidelines for quality assurance in mammography screening (1).
The chosen parameters of comparison are the proportions of tumours with diameter ≤ 10 mm, Stage II+ disease, ductal carcinoma in situ (DCIS), and node-negative cancers. Where possible, the malignancy grade of ductal carcinomas is also compared. Of treatment-related characteristics the proportions of breast conserving surgery (BCS) and of systemic therapy are compared, and as an indicator of the risk of afalse positive mammography, the recall rate is reported.
Since the organisation, the method of screening, the interval between screens, the time period, the age group offered screening, the number of participants in the studies, and compliance varies widely among the studies, these parameters are also listed. The breast cancer detection rate is listed as amarker of the efficiency of the screening programme.
The parameters are preferably reported from the prevalence round of screening, but often these results are published together with the results from the incidence rounds.
Furthermore, it is not consistently stated whether results refer to total number of cases detected inclusive carcinoma in situ or invasive cases only. Likewise, it is not always clear whether in situ cases refer to DCIS only or other forms of non-invasive disease as well.
None of the studies report all of the chosen parameters.
SCREENING GROUP
Exactly which group is reported as "screen-detected" is not consistently reported. In most studies "screen-detected" refers to the group actually participating in screening and with tumours detected at screening. In the randomised studies the "screened group" refers to the group randomised to screening and consists of those with screen-detected cancers, of those with cancers detected in intervals between screens, and of cancers in non-attenders (intention-to-treat principle).
In some of the population-based studies the screened group refers to the segment of the population offered screening. Since compliance and the detection rate varies widely, the impact of introduction of mammography screening in acommunity setting is most reliably assessed by reporting both the results from the group offered screening, and the resultsofthose actually participatinginscreening.
Wherepossible, screeningresults aretherefore reported here both on thegroup attendingfor screeningand on the population offered screening. AGEGROUP Mammography screening has shown largest efficacy in the age group >50( 8). Most of the reviewed studies, however, were begun before this knowledge became available, and therefore often include younger age groups. In many studies it is not possible to separate the different age groups and they are therefore reported as awhole. Where possible, focus is concentrated on the age group 50-69 years.
CONTROL GROUPS
Depending on type of study, the groups for comparison consist of the unscreened controls in the randomised studies, case-control probands, historical controls, and non-attenders in ascreening on service setting.
Further, the rate of interval cancers compared to the clinical incidence rate is used as am arker of the quality of screening.
Many studies only compare results from the first round with subsequent rounds without comparison with the background population.
As an example of ah istorical control, the Copenhagen programme is compared to the unscreened population in Copenhagen and ageographical control consisting of oth-er parts of Denmark prior to and after introduction of screening mammography.
This comparison relies on data from the Danish Breast Cancer Cooperative Group (DBCG)-database, whereto approximately 95 %o fi ncident breast cancers have been reported since 1977 with some variations according to time. Previous comparison of the DBCG database with the Danish Cancer Registry has shown ah igh degree of concordance between the registers (9).
The DBCG-database only holds records of the first primary breast cancer, and patients with second primaries are not recorded. Concerning the screen-detected cases, the data reported in this paper differ from those published previously (10) . This difference is mainly due to the fact that the screen-detected cases are here tabulated during the period when the final diagnosis was made, whereas the cases previously reported were tabulated during the period of positive mammography. Data review is still ongoing.
In order to facilitate comparison, indicators are reported as suggested by EU-guidelines (Table 1) .
RESULTS

EU-GUIDELINES
The desirable and acceptable levels of performance and surrogate indicators are listed in Table 1 .
Where not reported directly, numbers have been calculated if possible.
RANDOMISED STUDIES
Key indicators of the randomised studies are reported in Table 2 .
All studies have been terminated at least 15 years ago, most have concentrated on the age group >4 0, in the HIP study the mammographical technique was of poor standards as compared with today, and in 4 studies mammography +c linical examination was the method under study.
The studies were designed to demonstrate areduction in mortality, and clinical parameters are poorly reported.
SERVICE PROGRAMMES
Programmes comparing with historical controls are listed in Tables 3a nd 4 . Results from programmes comparing prevalence and incidence rounds are published in (11, 12, 13, 14, 7) , but since there were only minor differences between the prevalence and incidence rounds regarding tumour stage and breast cancer treatment, these studies are not mentioned further.
The main part of the Copenhagen data have previously been published (15, 16, 17) , but to some extent we refer to unpublished data (Table 4 ).
PROPORTION OF INVASIVE CANCERS ≤ 10 MM
The randomised trials most often report stage instead of tumour size. In the Two-county study (18) , 26 % of the screen-detected tumours were less than 10 mm, as opposed to 7%in the control group. The tumour size in the group randomised to screening is not re-ported, but in Östergötland (part of the Two-county), 33 %oftumours were smaller than 10 mm in this group as opposed to 12 %i nt he control group ( Table 2 ). An increased proportion of those randomised to mammography are reported as having stage I-disease compared to controls (Table 2 ).
In the Canadian trial small tumours (defined as < 2cm) are significantly more frequent in the screened group (19) . In the service programmes the proportion varies from 12-27 %inthe historical controls to 42-75 %i ni ncidence screening rounds (women attending screening only). In the population offered screening the frequency of small tumours varies from 29-37 %inCopenhagen to 72 %inFinland, the Finnisht umours defineda ss izeb elow 20 mm.A mong thosewith screen-detected cancers the proportion of small tumours is therefore large in the Finnish study, 72-75 %compared to 37-48 %inCopenhagen, where size is defined as ≤ 10 mm. (Tables 3a nd 4 ). Except Finland, the frequency of small tumours is lowest among interval cancers and non-attenders, 10-23 % (Table 3) , but the proportion of small tumours otherwise exceedst he desiredl evel of 25-30 %s tated in the EU-guidelines.
In Luxembourg, the proportion of tumours >20 mm was 56 %b efore the introduction of the screening programme, 27 %f or initial screening and 12 % for subsequent screening (20) .
PROPORTION OF STAGE II+ CANCERS OUT OF TOTAL CANCERS SCREEN-DETECTED
EU-guidelines recommend the fraction of stage II+ among screen detected cancers to be below 25 %. For comparison reasons, the measure of stage II+ cancers is also given for clinically diagnosed cancers in order to assess changes in stage distribution as as urrogate discriminator.
In the randomised trials the proportions of small and lower stage tumours are constantly larger in the group randomised to screening compared with the control group (Table 2) . When looking at the screendetected cancers only, the difference between clinically diagnosed and screen-detected cancer widens in the HIP, Kopparberg, Östergötland, Malmö, and Edinburgh trials (Table 2 ). In the two-county study asignificant reduction of stage II-cancers of 25 %(21) was found.
Asubgroup of the two-county study (Kopparberg, (22) ) showed significantly larger tumours and more with lymph node metastases in the control group, but the non-attenders and the interval cancers from the screening group weregroupedtogether withthe unscreened controls. Both in the randomised studies and in the service programmes, the fraction of stage II+ exceeds 50 %i nm ost of the clinically diagnosed cancers, and of the screen-detected cancers, only the Helsinki programme meets the criteria of 25 %s tated in the EU-guidelines (Tables 2-3) , (23) .
In Copenhagen, the proportion of stage II+ diminished from 65-57 %to40-43 %comparing historical controls with the population offered screening. Among the screen-detected cancers the fraction was reduced to 27-30 %, but it remained constantly above 60 %i nt he areas without screening in the rest of Denmark.
NODE-NEGATIVE DISEASE
Nodal status is rarely given in the studies, and where reported, the fraction of women with axillary surgery and the number of nodes removed is not stated.
It is often not clear how the cases of DCIS are assessed -whether they are counted as node-negative or omitted from the calculations.
In the randomised trials, the proportion of nodenegatives is higher in the group randomised to screening in the HIP, the Two-county and the Edinburgh studies, and this difference is more evident in those with screen-detected tumours. The HIP-trial found 70 %n ode-negative among those actually screened, which exactly matched EU-guidelines-criteria. No difference is seen between study and control groups in the Canadian trials (Table 2 ).
In some of the service screening studies comparing prevalence and incidence screens the proportions adhere to the guidelines (Table 3) , but the Finnish programme with 62-64 %n ode-negative did not achieve the acceptable levels in their first rounds.
In Copenhagen, counting invasive cases only, the proportion of node-negative disease increased concordant with the prevalence round in the population offered screening. Considering the cancers actually detected at screening, mammography led to amarked increase in node-negative cancers, and this increase was maintained in the incidence rounds (Table 4 ).
DUCTAL CARCINOMA IN SITU
According to EU-guidelines this fraction should preferably constitute 10-20 %ofall screen-detected cancers.
In the randomised studies it varies from 2-11 %in the control group to 10-16 %a mong the screened group, with only minor differences between the group randomised to screening and those actually participating in screening. The variation is of the same magnitude in the service programmes.
In Copenhagen, the average proportion of CIS (lobular in situ included) was 2-6 %without screening and 6-12 %i nt he age group offered screening (Table 4 ).
DUCTAL CARCINOMA MALIGNANCY GRADE III
No recommendation on acceptable levels exists for this indicator, and it is poorly reported in the studies.
The two-county-study reported as ignificant reduction of grade III-tumours in the study population especially in the age group 50-74 (24) .
In Copenhagen, no reduction of grade III-tumours was seen as an effect of screening -infact an increase was observed, compared to Copenhagen before screening, but the Copenhagen fraction of Grade IIItumours before screening was remarkably low compared to the rest of Denmark. The increase was most pronounced in the group with clinically diagnosed tumours. Likewise,1 2% of thes creen-detected tu-mours in Finland were grade III as opposed to 33 % and 50 %i ni nterval cancers and non-attenders, but the total numbers in this study are small (Table 3) .
BREAST-CONSERVING SURGERY
As with malignancy grading, no recommendation exists on this indicator, and it is poorly reported.
In the older, randomised studies the proportion ranges from 11-31 %with only minor differences between screen-and control group. In the newer service programmes, the proportion varies from 54-69 %.
In Southeast Netherlands the proportion of BCS increased from 31 %i n1 984 to 60 %i n1 989 (25) . Mammography screening was introduced in 1990, with full coverage in 1996. Mammography screening did not lead to an increase of BCS for the group as a whole, but the frequency increased among the screen-detected cancers (25) .
Before screening, only 6-15 %inboth Copenhagen and the rest of DK had BCS. In Copenhagen this proportion increased during screening to 31-48 %in the population offered screening, and to 44-59 % among the screen-detected cancers. In areas without screening this proportion only increased to 17-21 % (Table 4 ).
SYSTEMIC THERAPY
In the randomised Malmö trial 32 %o ft he control group as opposed to 19 %ofthe screen-detected cancers needed adjuvant systemic therapy (Table 2) .
In British Columbia, 64 %o ft he non-attenders as opposed to 52 %o ft he screen-detected cancers needed systemic treatment, but otherwise it is not reported.
In Copenhagen,anotable reductioninthe proportion offered systemic treatment was seen in the group offered screening, and it was even more pronounced in the group with cancers detected at screening (Table 4).
RECALL RATE AS PROPORTION OF SCREENED
Afalse positive mammography is one of the adverse effects of screening. Since this measure is not often reported the recall rate is used instead.
According to EU-guidelines this indicator should not exceed 7%at initial screen and 5%at subsequent screen.
In Luxembourga nd New Zealand ( 20, 14) t he initial recall rates were 11 and 12 %, but were within limits in subsequent rounds.
In Copenhagen, the recall rate in the incidence round reached the upper acceptable limit given in the EU-guidelines, but was acceptable in subsequent rounds (Table 4) .
DISCUSSION
Mammography screening is implemented in many different ways worldwide, extending from healthcare organized mammography recommended to broad age groups every year, to self-referred mammography and to publicly funded service screening offered to definite age groups and with personal invitations.
The practice of opportunistic screening outside programmes also varies widely from practically absent to consisting of about half of the total mammography activities. The background incidence of breast cancer, the re-screening interval, the compliance with, and the age groups offered screening also varies widely, which makes comparison between programmes and the estimation of the effect of screening difficult.
Furthermore, the background breast cancer incidence, the detection rate, the compliance, the recall rate and the interval cancer incidence are all interrelated factors when assessing the efficiency of mammography screening.
Ahigh breast cancer incidence should be reflected in ah igh breast cancer detection rate, which is only attainable with ahigh compliance. Aprerequisite for ahigh detection rate is also ahigh recall rate, which by itself is nott antamountt oah ighf alse positive rate. Alow detection rate, on the other hand, will inevitably lead to ahigh proportion of interval cancers.
When reviewing the impact of introduction of mammography screening in anon-screening community, an important effect of screening is the impact on the whole population. It is obvious, though, that screening only benefits those who participate, and unless the screening programme is of high quality and well accepted in the population, no general impact can be expected.
Assessment of tumour and treatment characteristics in thec omparisong roup is ap rerequisite, but very little pre-screening data exists. Most studies are retrospective, mixing screen-and clinically detected cancers (26, 27) , from non-systematically screening areas, or comparing screen-detected tumour characteristics with clinically detected tumours in younger and older age groups than the group offered screening. This will inevitably introduce bias in the favour of screening. It is known that the biology differs in the older and the younger age group, and that there is aselection bias in whom attending screening, tend-ing towards more advanced disease in non-attenders (2). The retrospective comparisons have shown smaller tumours, less likelihood of grade III-histology or lymph node metastases, and longer survival in screen detected cases (28) but lead-time and selection bias could be amajor contributor to this effect. Slowgrowing, less malignanttumours areeasierdetected by mammography, which introduce lengthtime bias when comparingwithacontrol group.
An improvement in stage distribution, naturally occurring concordant with the onset of screening could also easily be attributed to screening (6).
Borràs et al. (29) report on pre-screening values and by way of computer simulation estimates the foreseeable increase in DCIS, breast-conserving surgery, utilization of radiotherapy in the beginning of the screening programme, and the subsequent decrease in advanced stage disease after several years of screening.
De Koning et al. (30) report the frequency of opportunistic mammography, the biopsy ratio, the mode of surgery, and the adjuvant therapy before initiation of mammography screening. Via computer simulation the impact of screening on these parameters are calculated, but the actual data are not reported.
Most reliable data can be extracted from the randomised studies data on the clinical impact of screening, but detailed reports of the variables are often scarce.
The impact of introduction of mammography screening on tumour size is varying from study to study. The proportion of small tumours in control groups whether randomised, historical or non-attender is between 10 and 27 %, in the population offered screening between 22 and 37 %( with Finland as an outlier at 72 %), and among the screen-detected cancers between 14 and 48 %, again with Finland as an outlier at 75 %. The impact of screening on tumour size is therefore modest on the population offered screening, but pronounced in the group with screen-detected cancers.
Asubstantial decrease of advanced stage tumours wasseeninthe randomised studieswithanabsolute difference of 25 %inthe Two-county study. In service programmes, the difference in stage between screen-detected versus interval cancers and cancers in non-attenders is large as expected, but the difference is maintained when comparing historical controls with the group offered screening as in Copenhagen. Even when assessing only those attending for screening, Helsinki is the only programme reaching the acceptable level of stage II-tumours recommended by EU-guidelines. The study periods reported here were typically in the beginning of the 1990's, andthe programmes mighthaveimprovedsince.
The number of nodes removed and the proportion of women without axillary surgery are seldom reported, but since the studies were performed from 1963-1997, this must influence the estimates.
In the service programmes the acceptable level of 70-75 %node-negative stated in EU-guidelines were often reached. Astudy comparing those attending for screening with ahistorical control (Finland) found an increase in number of node-negatives in the screendetected. No striking effect was seen in the Copenhagen programme comparing nodal status in the group offered screening to ah istorical control and areas without screening at the population level, whereas the difference between the screen-detected cancers and the historical controls was more pronounced.
Conclusively, aclinical consequenceofmammography screening on nodal statusc an probably only be expected in the group actually participating in screening.
Mammographyscreening has overall led to an increaseinthe incidence of DCIS. In the UnitedStates an increase of 557 %was observed between 1973-93 as the annual incidence rate of DCIS was 2,4/100.000 in 1973 and 15,8/100.000 in 1992. DCIS accounted for 30-40 %ofall screen-detected cancers (31) .
Both in the randomised studies and in the service programmes the proportion of DCIS is considerably lower compared to the American figures, with amaximum of 25 %o ft he screen-detected cancers in Southampton.
EU-guidelines recommend aD CIS level between 10-20 %o fa ll screen-detected cancers, which is almost achieved by the studies reported here, and which is well below the American 30-40 %reported above.
Malignancy grading is poorly reported, and is also difficult to compare between programmes, since different grading systems exist. Within programmes, the grading system is more reliable. Asignificant reduction of grade III-tumours is seen in the Two-county study, and analyses of survival by grade showed that the mortality reduction age >50 could be attributed to the reduced fraction of grade III in the study population (24) . In the British Columbia-trial there was ahigher proportion of grade III-tumours in the nonattender group. In Copenhagen, the proportion of grade III-tumours was lower before screening compared to the rest of Denmark, and somewhat unexpectedly the proportion increased after introduction of screening, although more pronounced in the group with clinically diagnosed tumours.
Breast-Conserving Surgery has been increasingly utilized in the 1980s and 1990s and is the preferred surgical method for small tumours. In the absenceof screening it has been estimated that the proportion of BCS would constitute 50 %ofall breast cancer operations, but it has also been estimated that the larger amount of small tumours diagnosed through mammography screening would increase this proportion by 21 %atsteady state (32) .
Where reported, the proportion of BCS varies from 6-69 %. This probably reflects ad ifference in local practice and acalendar time effect more than the effect of mammography screening. Copenhagen is the only area wherem ammography screeningc ontributes substantially to the proportion of BCS.
Where reported, the women with screen-detected cancer had ah igher chance of avoiding adjuvant chemotherapy or endocrine treatment compared to clinically diagnosed breast cancer with an absolute difference of about 10 %.
The recall rate as an indicator of false positive mammography varies from 5-14 %. The Canadian trial, combining clinical examination with screening mammography had an excessively high rate of recalls, especially in the age-group 40-49 and with only am odest detection rate. Copenhagen had ah igh recall rate in the prevalence round, but had on the other hand the highest detection rate so far reported, and most programmes exceeding the acceptable levels of recall in the prevalence screening met the criteria in the incidence rounds.
In the Copenhagen programme, it is estimated that the risk of at least one false positive mammography amounted to 10 %with participation in three screening rounds (33) . The studies on the psychological distress after af alse positive mammography are conflicting. ANorwegian study found elevated levels of anxiety and depression at recall for mammography but normalisation after four weeks (34) . Ar eview found prolonged psychological distress after af alse positive mammography (35, 36) , while others report an increased adherence to the screening programme (37) .
It is difficult to assess the risk of overdiagnosis of breast cancer due to mammography screening, since the number of detected cancers in the beginning of thescreening period inevitably will increase because of lead time, but it has been estimated to constitute less than 2%of the total population (38) .
CONCLUSION
Thec linicalc onsequenceso fi ntroductiono fm ammography screening are generally poorly documented in most studies. Asignificant reduction in tumour stage and an increase in the incidence of DCIS are observed both in the population offered screening, and more pronounced in the cases actually diagnosed by mammography screening compared to clinically diagnosed cases. Where reported, the impact of mammography screening on treatment is areduction of the proportion of breast cancer patients treated with mastectomy, and areduction of the proportion needing adjuvant systemic therapy. The reports on the psychological consequences are conflicting.
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